Bilirubin, Impaired Conjugation Follow-up
- Author: Sandeep Mukherjee, MB, BCh, MPH, FRCPC; Chief Editor: Julian Katz, MD more...
Prognosis
- Most patients with Crigler-Najjar type I syndrome die in infancy.
- Patients with Crigler-Najjar type II often do well, even in the absence of therapy.
- The prognosis for Gilbert syndrome is excellent. In addition, epidemiologic studies have reported an association between Gilbert syndrome, hyperbilirubinemia, and a reduced risk of cardiovascular disease.[12, 13] The exact mechanism for this finding is unclear, but the antioxidant properties of bilirubin may be contributory in conjunction with heme oxygenase.[14, 15]
- The prognosis for physiologic jaundice is excellent.
- In breast milk jaundice, the prognosis is good; however, the bilirubin level needs to be closely monitored, with adjustments in care accordingly, to prevent persistent hyperbilirubinemia and its potential complications (ie, kernicterus in the fragile neonatal period).
McGrath M, Lepine J, Lee IM, et al. Genetic variations in UGT1A1 and UGT2B7 and endometrial cancer risk. Pharmacogenet Genomics. Mar 2009;19(3):239-43. [Medline].
Saeki M, Saito Y, Sai K, et al. A combinatorial haplotype of the UDP-glucuronosyltransferase 1A1 gene (#60-#IB) increases total bilirubin concentrations in Japanese volunteers. Clin Chem. Feb 2007;53(2):356-8. [Medline].
Saito A, Kawamoto M, Kamatani N. Association study between single-nucleotide polymorphisms in 199 drug-related genes and commonly measured quantitative traits of 752 healthy Japanese subjects. J Hum Genet. Jun 2009;54(6):317-23. [Medline].
Zhou YY, Lee LY, Ng SY, et al. UGT1A1 haplotype mutation among Asians in Singapore. Neonatology. 2009;96(3):150-5. [Medline].
Strassburg CP. Pharmacogenetics of Gilbert's syndrome. Pharmacogenomics. Jun 2008;9(6):703-15. [Medline].
Lankisch TO, Behrens G, Ehmer U, et al. Gilbert's syndrome and hyperbilirubinemia in protease inhibitor therapy--an extended haplotype of genetic variants increases risk in indinavir treatment. J Hepatol. May 2009;50(5):1010-8. [Medline].
Kweekel D, Guchelaar HJ, Gelderblom H. Clinical and pharmacogenetic factors associated with irinotecan toxicity. Cancer Treat Rev. Nov 2008;34(7):656-69. [Medline].
Cakmak A, Calik M, Atas A, Hirfanoglu I, Erel O. Can haptoglobin be an indicator for the early diagnosis of neonatal jaundice?. J Clin Lab Anal. 2008;22(6):409-14. [Medline].
Fox IJ, Chowdhury JR, Kaufman SS, et al. Treatment of the Crigler-Najjar syndrome type I with hepatocyte transplantation. N Engl J Med. May 14 1998;338(20):1422-6. [Medline].
Miranda PS, Bosma PJ. Towards liver-directed gene therapy for Crigler-Najjar syndrome. Curr Gene Ther. Apr 2009;9(2):72-82. [Medline].
Birraux J, Menzel O, Wildhaber B, et al. A step toward liver gene therapy: efficient correction of the genetic defect of hepatocytes isolated from a patient with Crigler-Najjar syndrome type 1 with lentiviral vectors. Transplantation. Apr 15 2009;87(7):1006-12. [Medline].
Lin JP, O'Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. Oct 3 2006;114(14):1476-81. [Medline].
Lin JP, Schwaiger JP, Cupples LA, O'Donnell CJ, et al. Conditional linkage and genome-wide association studies identify UGT1A1 as a major gene for anti-atherogenic serum bilirubin levels--the Framingham Heart Study. Atherosclerosis. Sep 2009;206(1):228-33. [Medline].
Vitek L, Schwertner HA. Protective effects of serum bilirubin on peripheral vascular disease. Ann Hepatol. Jan-Mar 2008;7(1):94-5. [Medline].
Schwertner HA, Vítek L. Gilbert syndrome, UGT1A1*28 allele, and cardiovascular disease risk: possible protective effects and therapeutic applications of bilirubin. Atherosclerosis. May 2008;198(1):1-11. [Medline].
Aono S, Adachi Y, Uyama E. Analysis of genes for bilirubin UDP-glucuronosyltransferase in Gilbert's syndrome. Lancet. Apr 15 1995;345(8955):958-9. [Medline].
Bosma PJ, Chowdhury JR, Bakker C. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert's syndrome. N Engl J Med. Nov 2 1995;333(18):1171-5. [Medline].
Chopra S. Disorders of the Liver. Philadelphia, Pa: Lea & Febiger; 1988:23-37.
Chopra S, May RJ. Pathophysiology of Gastrointestinal Diseases. Little Brown & Company;1989: 312-317.
Gabilan JC, Benattar C, Lindenbaum A. Clofibrate treatment of neonatal jaundice. Pediatrics. Oct 1990;86(4):647-8.
Kadakol A, Ghosh SS, Sappal BS. Genetic lesions of bilirubin uridine-diphosphoglucuronate glucuronosyltransferase (UGT1A1) causing Crigler-Najjar and Gilbert syndromes: correlation of genotype to phenotype. Hum Mutat. Oct 2000;16(4):297-306.
Schiff ER, Sorrell MF and Maddrey WC, editors. Schiff's Diseases of the Liver. 8th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 1999:151-74.
Seppen J, Bosma PJ, Goldhoorn BG. Discrimination between Crigler-Najjar type I and II by expression of mutant bilirubin uridine diphosphate-glucuronosyltransferase. J Clin Invest. Dec 1994;94(6):2385-91.
Tada K, Roy-Chowdhury N, Prasad V. Long-term amelioration of bilirubin glucuronidation defect in Gunn rats by transplanting genetically modified immortalized autologous hepatocytes. Cell Transplant. Nov-Dec 1998;7(6):607-16.
Vroemen JP, Blanckaert N, Buurman WA. Treatment of enzyme deficiency by hepatocyte transplantation in rats. J Surg Res. Sep 1985;39(3):267-75.

